Evolus Expands Aesthetic Portfolio with Exclusive U.S. Licensing Agreement for Profhilo®, Europe’s Leading Injectable Skin Quality Treatment
Evolus, Inc., a global performance beauty company focused on developing innovative consumer aesthetic brands, has announced an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States. The agreement represents a major strategic expansion for Evolus as it enters the rapidly growing skin quality injectable market, complementing its existing portfolio of neurotoxin and dermal filler products.
Profhilo® has established itself as the market-leading injectable treatment for skin quality across Europe and has gained significant international recognition since its commercial launch in 2015. Available in more than 70 countries and supported by millions of treatments worldwide, the product has become one of the most widely adopted injectable therapies designed specifically to improve skin quality rather than restore facial volume.
With this partnership, Evolus aims to bring the globally successful treatment to the U.S. market, where demand for minimally invasive cosmetic procedures continues to rise and consumers are increasingly seeking natural-looking aesthetic enhancements that emphasize skin health and regeneration.
Expanding into the Growing Skin Quality Category
The agreement marks Evolus’ first major entry into the skin quality segment, an area that has experienced rapid growth internationally but remains relatively underdeveloped in the United States.
Traditionally, injectable aesthetic treatments have focused primarily on reducing facial wrinkles through neuromodulators or restoring facial volume with dermal fillers. While these procedures remain highly popular, growing consumer awareness has shifted attention toward treatments that improve the overall appearance, texture, and health of the skin itself.
Skin quality injectables represent a distinct category within aesthetic medicine, targeting characteristics such as hydration, elasticity, firmness, smoothness, and skin radiance rather than structural volume enhancement.
Industry experts increasingly view skin quality treatments as the next evolution of injectable aesthetics, offering patients more subtle and regenerative outcomes that complement conventional cosmetic procedures.
By adding Profhilo® to its portfolio, Evolus is positioning itself to participate in this emerging market while broadening the range of treatment options available to healthcare professionals and patients.
Profhilo®’s Global Success
Since its introduction in 2015, Profhilo® has become one of the most recognized injectable aesthetic products worldwide.
The treatment is currently available in more than 70 countries, reflecting widespread international adoption by dermatologists, plastic surgeons, and aesthetic physicians.
According to the companies, more than 4.8 million Profhilo® treatments have been administered globally, demonstrating both strong physician confidence and sustained patient demand.
Its commercial success has established Profhilo® as the leading injectable product in the skin quality category across numerous European markets.
The extensive clinical experience accumulated through millions of treatments provides a substantial foundation as Evolus prepares to introduce the product into the United States following regulatory approval.
A Different Approach to Hyaluronic Acid
One of Profhilo®’s distinguishing features is its unique formulation of hyaluronic acid.
Traditional hyaluronic acid injectables are primarily designed as dermal fillers that restore lost facial volume, reshape facial contours, or improve structural support beneath the skin.
Profhilo®, however, has been developed for a different therapeutic purpose.
Rather than acting as a volumizing filler, the product is intended for superficial injection to improve overall skin quality by enhancing hydration, elasticity, firmness, and smoothness.
Its formulation allows hyaluronic acid to disperse broadly within treated tissues, supporting improvements in skin appearance without creating additional facial volume or altering natural facial contours.
This regenerative approach aligns with evolving patient preferences for subtle aesthetic enhancements that preserve natural facial characteristics while improving skin health.
Meeting Growing Consumer Demand
Consumer preferences within aesthetic medicine have evolved considerably over the past decade.
While wrinkle reduction and facial contouring remain important treatment goals, increasing numbers of patients are seeking procedures that provide healthier-looking skin rather than dramatic cosmetic changes.
Many individuals now prioritize:
- Improved skin hydration
- Enhanced elasticity
- Greater skin firmness
- Smoother texture
- More youthful skin quality
- Natural-looking aesthetic outcomes
These preferences have contributed to rapid growth in regenerative aesthetic treatments that stimulate the skin’s natural repair processes rather than relying solely on volumizing or wrinkle-relaxing procedures.
Evolus believes this shift creates a significant opportunity to expand the overall injectable aesthetics market by addressing patient needs that are not fully met by existing neurotoxins or dermal fillers.
Opportunity in the U.S. Market
Although skin quality injectables have become a routine component of aesthetic treatment plans throughout much of Europe, the category remains in its early stages in the United States.
This relative underdevelopment presents what Evolus views as a substantial commercial opportunity.
In Europe, many physicians routinely combine skin quality treatments with neurotoxins and dermal fillers to create comprehensive facial rejuvenation plans tailored to individual patient goals.
Such combination therapies allow practitioners to simultaneously address facial expression lines, volume loss, and skin health.
As awareness of skin quality treatments continues to grow among U.S. consumers and healthcare professionals, Evolus expects increasing demand for products capable of complementing existing injectable therapies.
The company believes Profhilo® could play a central role in establishing and expanding this emerging treatment category.
Leveraging Evolus’ Commercial Infrastructure
Under the terms of the licensing agreement, Evolus will assume responsibility for all development activities necessary to obtain U.S. regulatory approval for Profhilo®.
Following approval, the company will oversee commercialization, marketing, physician education, and product distribution throughout the United States.
Evolus intends to leverage its established commercial infrastructure, digital engagement platform, and customer relationships built through its existing aesthetic product portfolio.
The company has developed considerable expertise in launching consumer-focused aesthetic brands and believes these capabilities will support successful market introduction once regulatory clearance is achieved.
Its digital marketing capabilities and practitioner network may also help accelerate physician adoption while increasing consumer awareness of skin quality treatments.
Financial Structure Supports Long-Term Growth
The companies structured the agreement using what Evolus describes as a disciplined and capital-efficient business development approach.
Importantly, the licensing agreement requires no upfront payment, allowing Evolus to expand its product portfolio without significant immediate capital expenditures.
Instead, the collaboration utilizes a transfer-price economic model designed to maintain gross profit margins consistent with Evolus’ long-term financial objectives.
The company also emphasized that the agreement is not expected to affect previously announced financial guidance.
Specifically, Evolus stated that the partnership will not alter its:
- 2026 revenue outlook
- Operating expense projections
- Operating profit expectations
- Long-term 2028 revenue targets
- Profitability objectives
This structure enables the company to pursue strategic expansion while maintaining financial discipline.
Strengthening Relationships with Aesthetic Practices
The addition of Profhilo® also supports Evolus’ broader strategy of becoming a comprehensive partner for aesthetic healthcare providers.
Rather than offering only a single category of injectable products, the company continues expanding across multiple treatment areas.
Its portfolio now spans:
- Neurotoxins
- Dermal fillers
- Skin quality injectables
This broader offering allows aesthetic practices to source multiple treatment solutions from a single commercial partner while providing physicians with greater flexibility in designing individualized treatment plans.
As patient expectations continue evolving toward comprehensive facial rejuvenation, integrated product portfolios may become increasingly valuable for aesthetic clinics seeking efficient purchasing and consistent clinical support.
Leadership Highlights Strategic Importance
Evolus President and Chief Executive Officer David Moatazedi described Profhilo® as an important addition that aligns closely with the company’s long-term vision.
According to Moatazedi, the globally recognized product complements Evolus’ existing injectable portfolio while addressing a rapidly growing area of consumer demand.
He emphasized that skin quality represents one of the most innovative and promising segments within aesthetic medicine and suggested that the category could become the next major frontier for injectable treatments in the United States.
Moatazedi also noted that Evolus’ established commercial infrastructure and digital capabilities position the company to help define and accelerate growth within the emerging U.S. skin quality market.
IBSA General Manager Salvatore Cincotti expressed similar confidence in the collaboration.
He noted that Evolus has demonstrated strong capabilities in developing consumer-focused aesthetic brands and executing successful commercial strategies within the U.S. market.
According to Cincotti, the partnership provides an opportunity to broaden access to Profhilo® while introducing the skin quality category to physicians and patients in the world’s largest aesthetic medicine market.
The exclusive licensing and distribution agreement between Evolus and IBSA represents an important milestone in the evolution of injectable aesthetics in the United States.
By bringing Profhilo®—Europe’s leading injectable skin quality treatment—to the U.S., Evolus is expanding beyond traditional wrinkle reduction and facial volumization into regenerative aesthetic medicine focused on improving overall skin health.
Supported by extensive international clinical experience, millions of successful treatments, and widespread physician adoption across more than 70 countries, Profhilo® enters the U.S. development pathway with a strong global reputation.
As consumer demand continues shifting toward natural-looking, minimally invasive aesthetic procedures, the product has the potential to establish a new category within the American market. Combined with Evolus’ growing portfolio of injectable therapies and its customer-focused commercial strategy, the partnership strengthens the company’s long-term vision of becoming a leading global performance beauty organization while delivering innovative treatment options that address the evolving needs of patients and aesthetic healthcare professionals.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. It employs over 2,500 personnel worldwide, its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.